Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart’s Top Stock Pick. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Bayer Aktienges ADR (BAYRY)

Bayer Aktienges ADR (BAYRY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 56,901,996
  • Shares Outstanding, K 3,929,696
  • Annual Sales, $ 52,152 M
  • Annual Income, $ 1,183 M
  • 60-Month Beta 1.13
  • Price/Sales 1.07
  • Price/Cash Flow 4.98
  • Price/Book 1.37
Trade BAYRY with:
  • Price/Earnings ttm 6.60
  • Earnings Per Share ttm 2.15
  • Most Recent Earnings 0.29 on 11/08/22
  • Next Earnings Date N/A
  • Annual Dividend & Yield 0.35 (2.43%)
  • Most Recent Dividend 0.352 on 05/02/22
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/22
See More
  • Average Estimate 0.36
  • Number of Estimates 4
  • High Estimate 0.46
  • Low Estimate 0.28
  • Prior Year 0.36
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
12.5000 +15.84%
on 11/09/22
14.4900 -0.07%
on 11/25/22
+1.8501 (+14.65%)
since 10/25/22
3-Month
11.4100 +26.91%
on 09/28/22
14.4900 -0.07%
on 11/25/22
+0.8000 (+5.85%)
since 08/25/22
52-Week
11.4100 +26.91%
on 09/28/22
18.4500 -21.52%
on 04/11/22
+1.0950 (+8.18%)
since 11/24/21

Most Recent Stories

More News
Regeneron (REGN) Outperforms YTD: What's in Store for 2023?

Regeneron (REGN) has had a good run in 2022 so far and the momentum should continue in 2023 as well.

REGN : 736.23 (+0.12%)
SNY : 45.39 (+0.78%)
BAYRY : 14.4800 (+2.04%)
Why Bayer Aktiengesellschaft (BAYRY) is a Top Value Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

BAYRY : 14.4800 (+2.04%)
BAYRY vs. NVO: Which Stock Is the Better Value Option?

BAYRY vs. NVO: Which Stock Is the Better Value Option?

BAYRY : 14.4800 (+2.04%)
NVO : 118.79 (+0.81%)
Eli Lilly (LLY) Stock Up 26.7% YTD: What's in Store for 2023?

Lilly (LLY) expects to launch five new medicines by 2023-end, including Mounjaro for type II diabetes (already launched) and donanemab for early Alzheimer's disease.

MRK : 107.50 (+0.64%)
LLY : 365.25 (+0.98%)
VRTX : 312.98 (-1.01%)
BAYRY : 14.4800 (+2.04%)
AstraZeneca's (AZN) Imfinzi/Imjudo Combo Gets Another FDA Nod

AstraZeneca (AZN) gets its second FDA approval for the Imfinzi+Imjudo combo in non-small cell lung cancer (NSCLC) indication.

AZN : 66.17 (+0.08%)
MRK : 107.50 (+0.64%)
VRTX : 312.98 (-1.01%)
BAYRY : 14.4800 (+2.04%)
Bayer (BAYRY) Eylea Label Extension Gets CHMP Positive Opinion

Bayer (BAYRY) gets positive recommendation from the CHMP for label extension of ophthalmology drug Eylea for the treatment of preterm infants with retinopathy of prematurity.

REGN : 736.23 (+0.12%)
BAYRY : 14.4800 (+2.04%)
PBYI : 4.26 (-9.94%)
SNDX : 21.90 (+0.92%)
Sanofi (SNY), Regeneron Dupixent Gets CHMP Nod for Skin Disease

The CHMP recommends approval of Sanofi's (SNY) Dupixent for the treatment of prurigo nodularis, a chronic inflammatory skin disease.

REGN : 736.23 (+0.12%)
SNY : 45.39 (+0.78%)
VRTX : 312.98 (-1.01%)
BAYRY : 14.4800 (+2.04%)
Pharma Stock Roundup: Q3 Earnings of BAYRY, AZN, EU Nod for AZN, SNY RSV Vaccine

Bayer (BAYRY) and AstraZeneca (AZN) announce third-quarter results. AstraZeneca and Sanofi's (SNY) RSV vaccine, nirsevimab gets approval in Europe.

SNY : 45.39 (+0.78%)
AZN : 66.17 (+0.08%)
GSK : 33.99 (+0.89%)
BAYRY : 14.4800 (+2.04%)
Kodiak Sciences' (KOD) Q3 Earnings Beat, Eye Candidate in Focus

Kodiak Sciences (KOD) reports a narrower-than-expected loss for the third quarter of 2022. The focus is on the lead candidate, KSI-301, developed for treating various retinal vascular diseases.

REGN : 736.23 (+0.12%)
BAYRY : 14.4800 (+2.04%)
ASLN : 0.6000 (+0.62%)
KOD : 7.54 (+2.03%)
AstraZeneca's (AZN) Q3 Earnings Beat, EPS Growth View Up

AstraZeneca (AZN) beats third-quarter estimates for earnings while sales come in line. AZN raises its 2022 earnings growth guidance, keeping its sales forecast unchanged.

AZN : 66.17 (+0.08%)
MRK : 107.50 (+0.64%)
VRTX : 312.98 (-1.01%)
BAYRY : 14.4800 (+2.04%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Average short term outlook on maintaining the current direction.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Key Turning Points

3rd Resistance Point 14.6433
2nd Resistance Point 14.5667
1st Resistance Point 14.5233
Last Price 14.4800
1st Support Level 14.4033
2nd Support Level 14.3267
3rd Support Level 14.2833

See More

52-Week High 18.4500
Fibonacci 61.8% 15.7607
Fibonacci 50% 14.9300
Last Price 14.4800
Fibonacci 38.2% 14.0993
52-Week Low 11.4100

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar